Krystal Biotech FY2026 EPS Forecast Raised by HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - HC Wainwright lifted their FY2026 earnings per share estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, April 28th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $6.30 per share for the year, up from their prior estimate of $6.23. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's FY2027 earnings at $8.56 EPS and FY2028 earnings at $9.85 EPS.

KRYS has been the topic of a number of other reports. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective on the stock. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $222.71.

Krystal Biotech Stock Down 14.8 %

KRYS stock traded down $24.00 during trading on Thursday, hitting $138.30. The company had a trading volume of 834,054 shares, compared to its average volume of 297,004. Krystal Biotech has a 12 month low of $137.38 and a 12 month high of $219.34. The firm has a 50-day moving average price of $174.63 and a 200-day moving average price of $171.10. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 45.95 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.35 by ($0.15). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently bought and sold shares of the company. Crossmark Global Holdings Inc. increased its position in Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after buying an additional 63 shares during the period. US Bancorp DE boosted its holdings in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after buying an additional 82 shares in the last quarter. Xponance Inc. raised its position in shares of Krystal Biotech by 4.9% during the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after purchasing an additional 88 shares during the last quarter. Finally, New York State Teachers Retirement System raised its holdings in shares of Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after acquiring an additional 100 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).